Veru Inc. develops late clinical-stage biopharmaceutical programs for cardiometabolic and inflammatory diseases. Company news centers on clinical development of enobosarm, an oral selective androgen receptor modulator being studied with GLP-1 receptor agonist therapy to make weight reduction more selective for fat loss while preserving lean mass, physical function, and bone.
Recurring updates also cover sabizabulin, an oral microtubule disruptor being developed for chronic inflammation related to atherosclerotic cardiovascular disease. Veru’s announcements commonly include fiscal results, business updates, clinical-study progress, regulatory feedback, scientific presentations, and conference webcasts tied to its small-molecule pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Veru Inc. (NASDAQ: VERU), a biopharmaceutical company, will host a conference call and audio webcast on May 11, 2023, at 8:00 a.m. ET to discuss its fiscal 2023 Q2 financial results and provide a business update. Interested investors can access the call through the company's website or by dialing specified telephone numbers. Veru is focused on developing treatments for breast cancer and SARS-CoV-2, with ongoing clinical trials for its candidates, including enobosarm for metastatic breast cancer and sabizabulin for COVID-19. Sabizabulin has shown a statistically significant 51.6% reduction in deaths in a Phase 3 trial. The company plans to conduct further trials and has received Fast Track designation from the FDA for its COVID-19 treatment.
Veru Inc. (NASDAQ: VERU) has announced the sale of its ENTADFI® business to Blue Water Vaccines, Inc. for a total of $20 million, with potential additional earnings of up to $80 million based on sales milestones. The deal includes an upfront payment of $6 million and scheduled payments of $4 million in fiscal 2023 and $10 million in fiscal 2024. This move aims to provide Veru with the financial flexibility needed to further develop its drug candidates, namely enobosarm for metastatic breast cancer and sabizabulin for SARS-CoV-2 related complications, with Phase 3 data anticipated in 2024. The company is also advancing multiple studies focusing on infectious diseases and oncology.